Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Core Insights - Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases [3] - The company will participate in a fireside chat at Guggenheim's SMID Cap Biotech Conference on February 5, 2025 [1] Company Overview - Cabaletta Bio is developing engineered T cell therapies through its CABA™ platform, which includes two complementary strategies aimed at treating a broad range of autoimmune diseases [3] - The lead strategy, CARTA, focuses on the investigational therapy rese-cel, a fully human CD19-CAR T cell therapy containing 4-1BB, currently evaluated in the RESET™ clinical development program [3] - The RESET™ program spans multiple therapeutic areas, including rheumatology, neurology, and dermatology [3] - The company's headquarters and labs are located in Philadelphia, PA [3] Event Information - A live webcast of the presentation at the conference will be available on the company's website, with replays accessible for 30 days [2]